194 related articles for article (PubMed ID: 35030298)
1. TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells.
Wang H; Wang X; Xu L; Zhang J
FEBS Open Bio; 2022 Mar; 12(3):616-626. PubMed ID: 35030298
[TBL] [Abstract][Full Text] [Related]
2. Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Boyko-Fabian M; Niehr F; Distel L; Budach V; Tinhofer I
PLoS One; 2014; 9(6):e98867. PubMed ID: 24927258
[TBL] [Abstract][Full Text] [Related]
3. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
Liu Q; Hilsenbeck S; Gazitt Y
Blood; 2003 May; 101(10):4078-87. PubMed ID: 12531793
[TBL] [Abstract][Full Text] [Related]
6. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
[TBL] [Abstract][Full Text] [Related]
7. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
8. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
Wang R; Liu C; Xia L; Zhao G; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2012 Dec; 18(24):6690-701. PubMed ID: 23082001
[TBL] [Abstract][Full Text] [Related]
9. Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer.
Nooshinfar E; Bashash D; Safaroghli-Azar A; Bayati S; Rezaei-Tavirani M; Ghaffari SH; Akbari ME
Biomed Pharmacother; 2016 Oct; 83():456-465. PubMed ID: 27427852
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
11. Arsenic Trioxide inhibits Activation of Hedgehog Pathway in Human Neuroblastoma Cell Line SK-N-BE(2) Independent of Itraconazole.
Liu X; Wang Z; Xiong X; Li C; Wu Y; Su M; Yang S; Zeng M; Weng W; Huang K; Zhou D; Fang J; Xu L; Li P; Zhu Y; Qiu K; Ma Y; Lei J; Li Y
Anticancer Agents Med Chem; 2023; 23(20):2217-2224. PubMed ID: 37888819
[TBL] [Abstract][Full Text] [Related]
12. MDM2-mediated Inhibitory Effect of Arsenic Trioxide on Small Cell Lung Cancer Cell Line by Degrading Mutant p53.
Wang YS; Yin JZ; Shi XQ; Zhao XW; Li B; Yang MH
Anticancer Agents Med Chem; 2023; 23(16):1829-1837. PubMed ID: 37259217
[TBL] [Abstract][Full Text] [Related]
13. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Lunghi P; Giuliani N; Mazzera L; Lombardi G; Ricca M; Corradi A; Cantoni AM; Salvatore L; Riccioni R; Costanzo A; Testa U; Levrero M; Rizzoli V; Bonati A
Blood; 2008 Sep; 112(6):2450-62. PubMed ID: 18583568
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Kryeziu K; Jungwirth U; Hoda MA; Ferk F; Knasmüller S; Karnthaler-Benbakka C; Kowol CR; Berger W; Heffeter P
Mol Cancer Ther; 2013 Jun; 12(6):1073-84. PubMed ID: 23548265
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Yan W; Jung YS; Zhang Y; Chen X
PLoS One; 2014; 9(8):e103497. PubMed ID: 25116336
[TBL] [Abstract][Full Text] [Related]
16. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Xia Y; Fang H; Zhang J; Du Y
Exp Biol Med (Maywood); 2013 Aug; 238(8):932-42. PubMed ID: 23883479
[TBL] [Abstract][Full Text] [Related]
17. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH
Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.
Doudican NA; Bowling B; Orlow SJ
Leuk Res; 2010 Feb; 34(2):229-34. PubMed ID: 19540589
[TBL] [Abstract][Full Text] [Related]
19. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.
Lunghi P; Costanzo A; Levrero M; Bonati A
Blood; 2004 Jul; 104(2):519-25. PubMed ID: 15031205
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Lam SK; Li YY; Zheng CY; Ho JC
Int J Oncol; 2015 Jan; 46(1):113-22. PubMed ID: 25335113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
